Jazz Pharmaceuticals plc
JAZZ evidence brief
What we can confirm
- BioSniper Score:
- 7.4 / 10
- Market Cap:
- $15.58B
- Lead Asset:
- defitelio (Approved)
What it means
What to watch
Prepared research question
What matters most for JAZZ—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · JAZZ
Jazz Pharmaceuticals plc (JAZZ) is a global biopharmaceutical company focused on rare diseases, with a diverse portfolio of marketed medicines addressing epilepsies, cancers, and sleep disorders, and a pipeline of early- to late-stage investigational therapies.
Key risk: Zepzelca confirmatory trial failure
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 10 pipeline candidates · 49 clinical trials · 9 catalysts · 7 FDA decisions for Jazz Pharmaceuticals plc.
Jazz Pharmaceuticals plc (JAZZ) is a global biopharmaceutical company focused on rare diseases, with a diverse portfolio of marketed medicines addressing epilepsies, cancers, and sleep disorders, and a pipeline of early- to late-stage investigational therapies.
- Cash & equivalents of $1,619.8M as of 2026-06-30 [sec]
- Total revenue of $1,208.3M and net income of $192.8M as of 2026-06-30 [sec]
- Shareholders' equity of $4,801.7M and total debt of $4,395.0M as of 2026-06-30 [sec]
- Portfolio includes leading therapies for epilepsies, cancers, and sleep disorders [sec_mda · as of 2026-08-03]
- Phase 3 LAGOON confirmatory trial for Zepzelca in second-line metastatic SCLC did not meet its primary OS endpoint [sec_mda · as of 2026-08-03]
What works
- Strong cash position of $1,619.8M as of 2026-06-30 provides financial flexibility for R&D and corporate development [sec]
- Focus on rare diseases with high unmet needs and small patient populations enables efficient, concentrated commercialization [sec_mda · as of 2026-08-03]
- Diverse pipeline includes multiple ongoing Phase 1/2/3 trials across epilepsies, cancers, and CNS disorders [sec_mda · as of 2026-08-03]
- Strategic corporate development and licensing agreements expand early-stage neuroscience and oncology pipeline [sec_mda · as of 2026-08-03]
What to weigh
- Phase 3 LAGOON trial for Zepzelca in second-line metastatic SCLC failed to meet its primary overall survival endpoint [sec_mda · as of 2026-08-03]
- High total debt of $4,395.0M as of 2026-06-30 relative to shareholders' equity of $4,801.7M [sec]
- Commercialization of products like Ziihera, Modeyso, Zepzelca, Rylaze, Vyxeos, and Defitelio faces pricing/reimbursement pressures and complex global supply chains [sec_mda · as of 2026-08-03]
- Increased regulatory scrutiny over accelerated approvals could lead to restriction or withdrawal of products [sec_mda · as of 2026-08-03]
From the filings
Quoted directly from source documents.
Phase 3 LAGOON trial did not meet primary OS endpoint
“In June 2026, we announced top-line results from the LAGOON trial, which did not meet its primary OS endpoint evaluating Zepzelca as monotherapy or in combination with irinotecan compared with investigators' choice of topotecan or irinotecan.”
SEC MD&A · August 3, 2026
Focus on rare diseases with high unmet needs
“We focus on rare diseases, which often have high unmet needs and small patient populations, resulting in efficient, concentrated call points.”
SEC filings · August 3, 2026
Catalyst timeline
- 2026-10-30 · Phase3_Start: Phase 3 trial of Cannabidiol Oral Solution in DEE — A multicenter, randomized, double-blind, placebo-controlled study evaluating CBD-OS in participants aged 1 year and older with developmental and epileptic encephalopathy.
- 2026-11-30 · Phase2_Start: Phase 2 trial of Lurbinectedin + Durvalumab in ES-SCLC — Open-label, single-arm study of lurbinectedin in combination with durvalumab as first-line maintenance therapy in extensive-stage small-cell lung cancer.
- 2026-12-01 · Phase2_Start: Phase 2 trial of ONC201 for refractory meningioma — A pilot, open-label study of ONC201 for refractory meningioma.
- 2026-12-31 · Phase2_Start: Phase IIb study of Nabiximols for spasticity due to NMOSD — Double-blind, randomized, placebo-controlled, crossover study evaluating safety and efficacy of nabiximols in subjects with spasticity due to neuromyelitis optica spectrum disorders.
Risks & what to watch (4)›
Key risks
- Zepzelca confirmatory trial failure — Phase 3 LAGOON trial did not meet primary OS endpoint, leading to a labeling supplement to remove indication [sec_mda · as of 2026-08-03]
- High debt leverage — Total debt of $4,395.0M nearly equals shareholders' equity of $4,801.7M as of 2026-06-30 [sec]
- Regulatory scrutiny on accelerated approvals — Increased scrutiny could lead to restriction or withdrawal of products if endpoints are not met [sec_mda · as of 2026-08-03]
- Pricing and reimbursement pressures — Commercializing key products faces increasing pricing/reimbursement pressures and complex global supply chains [sec_mda · as of 2026-08-03]
What to watch
- FDA review and action on labeling supplement for Zepzelca following LAGOON trial failure [sec_mda · as of 2026-08-03]
- Phase 3 trial start for Cannabidiol Oral Solution in Developmental and Epileptic Encephalopathy (DEE) on 2026-10-30 [catalyst]
- Phase 2 trial start for Lurbinectedin + Durvalumab in extensive-stage SCLC on 2026-11-30 [catalyst]
- Phase 2 trial start for ONC201 in refractory meningioma on 2026-12-01 [catalyst]
Sources: Catalysts · SEC filings · SEC MD&A · Generated October 12, 2026 · How we verify sources →
Run Jazz Pharmaceuticals plc through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Jazz Pharmaceuticals plc facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Cash runway data unavailable
D/E 1.31 · 10% dilution
Lead: Approved
10 candidates
9 upcoming, next in ~16d
0 buys · 10 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
568
Total value held
$11.50B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 5,591,700 | $1.06B |
| vanguard portfolio management llc | 2,983,242 | $564.0M |
| capital world investors | 2,673,376 | $505.4M |
| vanguard capital management llc | 2,648,333 | $500.7M |
| fmr llc | 2,275,762 | $430.2M |
| franklin resources inc | 1,958,940 | $370.3M |
| dimensional fund advisors lp | 1,895,215 | $358.3M |
| state street corp | 1,891,646 | $357.6M |
| ecor1 capital, llc | 1,706,469 | $322.6M |
| bank of new york mellon corp | 1,679,371 | $317.5M |
Showing top 10 of 568 institutional holders of Jazz Pharmaceuticals plc. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 9.8%
- Days to cover
- 6.1
- Shares short
- 5,240,459
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
JAZZ short interestGovernance
Frequently asked questions
What is the AI investment thesis for Jazz Pharmaceuticals plc?
Jazz Pharmaceuticals plc (JAZZ) is a global biopharmaceutical company focused on rare diseases, with a diverse portfolio of marketed medicines addressing epilepsies, cancers, and sleep disorders, and a pipeline of early- to late-stage investigational therapies.
What is Jazz Pharmaceuticals plc's lead drug candidate?
Jazz Pharmaceuticals plc's most advanced tracked candidate is defitelio (Approved).
What is Jazz Pharmaceuticals plc's next catalyst?
Jazz Pharmaceuticals plc's next tracked catalyst is a Phase3_Start event — "Phase3_Start: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Cannabidiol Oral Solution (CBD-OS, JZP926-OS) in Participants Aged 1 Year and Older With Developmental and Epileptic Encephalopathy (DEE)" — expected October 30, 2026.
Who is the CEO of Jazz Pharmaceuticals plc?
Ms. Renee D. Gala is the chief executive officer of Jazz Pharmaceuticals plc (JAZZ).
Where is Jazz Pharmaceuticals plc headquartered?
Jazz Pharmaceuticals plc (JAZZ) is headquartered in Dublin, Ireland.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.